Inspire Medical Systems, Inc. (INSP)
NYSE: INSP · Real-Time Price · USD
187.77
+2.35 (1.27%)
Dec 20, 2024, 4:00 PM EST - Market closed
Inspire Medical Systems Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for INSP stock have an average target of 232.55, with a low estimate of 197 and a high estimate of 260. The average target predicts an increase of 23.85% from the current stock price of 187.77.
Analyst Consensus: Buy
* Price targets were last updated on Nov 20, 2024.
Analyst Ratings
The average analyst rating for INSP stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 2 | 2 | 3 | 3 |
| Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Hold | 4 | 4 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 13 | 12 | 12 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $220 → $255 | Hold → Strong Buy | Upgrades | $220 → $255 | +35.80% | Nov 20, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $260 | Buy | Reiterates | $260 | +38.47% | Nov 5, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $255 → $260 | Buy | Reiterates | $255 → $260 | +38.47% | Nov 5, 2024 |
| Stifel | Stifel | Hold Reiterates $170 → $200 | Hold | Reiterates | $170 → $200 | +6.51% | Nov 5, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $187 → $198 | Hold | Maintains | $187 → $198 | +5.45% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
812.01M
from 624.80M
Increased by 29.96%
Revenue Next Year
970.51M
from 812.01M
Increased by 19.52%
EPS This Year
1.35
from -0.72
EPS Next Year
2.03
from 1.35
Increased by 50.37%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 838.2M | 1.0B | 1.2B | |||
| Avg | 812.0M | 970.5M | 1.1B | |||
| Low | 777.1M | 916.1M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 34.2% | 25.0% | 25.1% | |||
| Avg | 30.0% | 19.5% | 17.9% | |||
| Low | 24.4% | 12.8% | 9.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.47 | 2.59 | 4.82 | |||
| Avg | 1.35 | 2.03 | 3.23 | |||
| Low | 1.18 | 1.47 | 2.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 92.0% | 137.3% | |||
| Avg | - | 50.4% | 59.1% | |||
| Low | - | 8.8% | 11.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.